

Agencia Española de Medicamentos y Productos Sanitarios

C/Campezo 1, Edificio 8 28022 – Madrid España (Reference Member State)


DECENTRALISED PROCEDURE

PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

ACEPROLAB 5 mg/ml SOLUTION FOR INJECTION

CORREO ELECTRÓNICO







PRODUCT SUMMARY

EU Procedure number	ES/V/0380/001/DC	
Name, strength and pharmaceutical form	Aceprolab 5 mg/ml solution for injection	
Applicant	Labiana Life Sciences S.A. Calle Venus, 26 Poligono Industrial Can Parellada 08228. Terrassa (Barcelona) - Spain	
Active substance(s)	Acepromazine maleate	
ATC Vetcode	QN05AA04	
Target species	Dogs, cats and horses not intended for human consumption.	
Indication for use	Dogs and cats: - Tranquiliser for the handling of difficult animals and / or to stressful situations for the animal (clinical examinations, diagnostic tests, motion sickness, etc.). - Premedication before anaesthesia, allowing to reduce the necessary doses of analgesics and general anaesthetics and counteracting the emetic effect of opiates. - In the postoperative, to provide a quiet awakening. Horses not intended for human consumption: -Tranquilization without subsequent anaesthesia. -Premedication before anaesthesia -Coadjuvant in equine colic treatment.	



MODULE 2

The Summary of Product Characteristics (SPC) for this product is available on the Heads of Medicines Agencies website (http://www.hma.eu).

MINISTERIO DE SANIDAD

Agencia española de medicamentos y productos sanitarios





PUBLIC ASSESSMENT REPORT

Legal basis of original application	Decentralised application in accordance with Article 13(1) of Directive 2001/82/EC as amended.
Date of completion of the original decentralised procedure	01/07/2020
Date product first authorised in the ReferenceMemberState (MRP only)	N/A
Concerned Member States for original procedure	HU

I. **SCIENTIFIC OVERVIEW**

The product is produced and controlled using validated methods and tests, which ensure the consistency of the product released on the market.

The overall risk/benefit analysis is in favour of granting a marketing authorisation.

QUALITY ASPECTS II.

A. Qualitative and quantitative particulars

The product contains Acepromazine maleate (5mg) as active substance and benzoic acid, sodium citrate, citric acid and water for injection as excipients.

The container/closure system is amber glass vial Type II, with a nominal volume of 25 ml and 100 ml, closed with chlorobutyl rubber stopper and aluminium capsule.

The choice of the formulation is justified.

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

> **MINISTERIO** DE SANIDAD

Agencia española de medicamentos y productos sanitarios



B. Method of Preparation of the Product

The product is manufactured fully in accordance with the principles of good manufacturing practice from a licensed manufacturing site.

Process validation data on the product have been presented in accordance with the relevant European guidelines.

C. Control of Starting Materials

The active substance is Acepromazine maleate, an established substance described in the British Pharmacopoeia. The active substance is manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

Scientific data has been provided according to the Active Substance Master File (ASMF) procedure. The provided information is considered appropriate.

Satisfactory TSE information has been provided in compliance with the Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Human and Veterinary Medicinal Products.

D. Control on intermediate products

Not applicable.

E. Control Tests on the Finished Product

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product.

Satisfactory validation data for the analytical methods have been provided.

Batch analytical data from the proposed production site have been provided demonstrating compliance with the specification.

F. Stability

Stability data on the active substance has been provided in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approved conditions.



ES/V/0380/001/DC Application for Decentralised Procedure Publicly available assessment report

Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the product throughout its shelf life (30 months) when stored under the approved conditions.

Appropriate data have been provided to support the in-use shelf-life of the product.

G. Other Information

Not applicable.



III. SAFETY AND RESIDUES ASSESSMENT (PHARMACOTOXICOLOGICAL)

III.A Safety Testing

Pharmacological Studies

As this is a generic application according to Article 13 and bioequivalence with the reference product has been demonstrated, results of pharmacological tests are not required.

The pharmacological aspects of this product are identical to the reference product.

Toxicological Studies

As this is a generic application according to Article 13 and bioequivalence with the reference product has been demonstrated, results of toxicological tests are not required.

The toxicological aspects of this product are identical to the reference product.

User Safety

Although this is a generic application according to Article 13 and bioequivalence with the reference product has been demonstrated, the applicant has provided a brief user safety assessment broadly in accordance with the relevant guideline.

Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product.

Environmental Risk Assessment

A Phase I environmental risk assessment (ERA) was provided according to the CVMP/VICH guidelines.

The environmental risk assessment can stop in Phase I and no Phase II assessment is required because the veterinary medicinal product will only be used in non-food animals.



IV. CLINICAL ASSESSMENT (EFFICACY)

IV.A Pre-Clinical Studies

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, efficacy studies are not required. The efficacy claims for this product are equivalent to those of the reference product.

IV.B Clinical Studies

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, efficacy studies are not required. The efficacy claims for this product are equivalent to those of the reference product.



V. OVERALL CONCLUSION AND BENEFIT- RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the risk benefit profile for the target species is favourable and the quality and safety of the product for humans and the environment is acceptable.

MINISTERIO DE SANIDAD

Agencia española de medicamentos y productos sanitarios







POST-AUTHORISATION ASSESSMENTS

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the veterinary Heads of Agencies website (www.hma.eu).

This section contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

Summary of change (Application number)	Approval date
Addition of horses not intended for human consumption as target specie. ES/V/0380/001/A/002/G	22/01/2024